Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

JOURNAL ARTICLE published October 2014 in The Lancet Oncology

Authors: Gunter von Minckwitz | Fabio Puglisi | Javier Cortes | Eduard Vrdoljak | Norbert Marschner | Christoph Zielinski | Cristian Villanueva | Gilles Romieu | István Lang | Eva Ciruelos | Michele De Laurentiis | Corinne Veyret | Sabine de Ducla | Ulrich Freudensprung | Stefanie Srock | Joseph Gligorov